| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6488963 | PURDUE PHARMA LP | Hot-melt extrudable pharmaceutical formulation |
Jun, 2017
(6 years ago) | |
| US9198863 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9023401 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9669023 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9289391 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9675611 | PURDUE PHARMA LP | Methods of providing analgesia |
Oct, 2020
(3 years ago) | |
| US9682077 | PURDUE PHARMA LP | Methods of providing analgesia |
Oct, 2020
(3 years ago) | |
| US9517236 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9205056 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9572804 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9669024 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9060940 | PURDUE PHARMA LP | Controlled release hydrocodone |
Oct, 2020
(3 years ago) | |
| US9056052 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US6733783 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2021
(2 years ago) | |
| US8647667 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2021
(2 years ago) | |
| US8551520 | PURDUE PHARMA LP | Controlled release hydrocodone |
Oct, 2021
(2 years ago) | |
| US8361499 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2021
(2 years ago) | |
| US8529948 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 8 months ago) | |
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(10 months ago) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(10 months ago) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(4 months ago) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(4 months ago) | |
| US11844865 | PURDUE PHARMA LP | Abuse-proofed oral dosage form |
Feb, 2025
(9 months from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095615 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486413 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9775809 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9084816 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486412 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492390 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095614 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9545380 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9750703 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9861584 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9872837 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9572779 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US8808740 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
Hysingla Er is owned by Purdue Pharma Lp.
Hysingla Er contains Hydrocodone Bitartrate.
Hysingla Er has a total of 42 drug patents out of which 22 drug patents have expired.
Expired drug patents of Hysingla Er are:
- US6488963
- US9198863
- US9023401
- US9669023
- US9289391
- US9675611
- US9682077
- US9517236
- US9205056
- US9572804
- US9669024
- US9060940
- US9056052
- US6733783
- US8647667
- US8551520
- US8361499
- US8529948
- US9675610
- US10369109
- US10130591
- US8309060
Hysingla Er was authorised for market use on 20 November, 2014.
Hysingla Er is available in tablet, extended release;oral dosage forms.
Hysingla Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate.
The generics of Hysingla Er are possible to be released after 21 December, 2031.
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
HYSINGLA ER family patents
